Buzdar AU et al. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004;10(3):211-7. Abstract

Cameron DA et al. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Proc ASCO 2004;Abstract 628.

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Iaffaioli RV et al. Preliminary data of GOIM 2107 study: Multicenter phase II study of sequential hormonotherapy with anastrozole/exemestane in metastatic breast disease. Proc ASCO 2004;Abstract 820.

Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):15-8. Abstract

Jones SE et al. A retrospective analysis of the proportion of patients responding for > 1 year in two phase III studies of fulvestrant vs. anastrozole. Proc ASCO 2004;Abstract 737.

Kaufmann M et al. Exemestane improves survival in metastatic breast cancer: Results of a phase III randomized study. Clin Breast Cancer 2000; (1 Suppl 1):15-8. Abstract

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Milla-Santos A et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003;26(3):317-22. Abstract

Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract

Mouridsen H et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional ability. Oncologist 2004;9(5):489-96. Abstract

Nabholtz JM et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer 2003;39(12):1684-9. Abstract

Okubo S et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004;90(1):236-44. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Paridaens R et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) — A randomized phase III trial of the EORTC Breast Group. Proc ASCO 2004;Abstract 515.

Petruzelka L et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy — results from a compassionate use program. Proc ASCO 2004;Abstract 730.

Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004;9(5):507-17. Abstract

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Rose C et al. An open randomised trial of secondline endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39(16):2318- 27. Abstract

Sahmoud T. Clinical trial designs for further development of fulvestrant (Faslodex). Poster. Lynn Sage Breast Cancer Symposium, September 2003.

Sokolowicz LE, Gradishar WJ. Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer. Clin Breast Cancer 2004;5 Suppl 1:S24-30. Abstract

Thurlimann B et al. Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 — a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85(3):247-54. Abstract

Thurlimann B et al. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39(16):2310-7. Abstract

Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract